Current treatment options |
pasireotide, ketoconazol, mitotane, metyrapone, mifeproston. |
Therapeutic value |
Possible added value |
Substantiation |
11β-hydroxylase remmer, die minder interacties met andere geneesmiddelen lijkt te hebben dan ketoconazol. LINC-3 studie heeft primaire eindpunt gehaald. |
Duration of treatment |
Average 2 year / years |
Frequency of administration |
1 times a day |
Dosage per administration |
30 mg |
References |
NCT02697734; Fleseriu et al. Pituitary. 2016 Apr;19(2):138-48; Bertagna X et al. LCI699. J Clin Endocrinol Metab. 2014;99(4):1375–1383; Aramani S, Clin Drug Investigat. 2017; Scrip23 juli 2018 |